Compare Moderna, Inc. (MRNA) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Orion Office REIT Inc — how do they compare? Moderna, Inc. trades at $224.78 (market cap $78.65B), while Orion Office REIT Inc trades at $2.18 (market cap $125.50M). The key difference: Moderna, Inc. is far larger — about 626.7× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.64% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Orion Office REIT Inc for 33 Days on average.
| MRNA | ONL | |
|---|---|---|
Market Cap | $78.65B | $125.50M |
Volume | 37,373,437 | 303,276 |
Sector | Health | Real Estate |
52-Week High | $203.46 | $3.00 |
52-Week Low | $22.36 | $1.93 |
Typical Hold Time | 59 Days | 33 Days |
Enterprise Value | $74.80B | $542.43M |
Dividend Yield | — | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.
Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.
ONL trades at $2.20, down 3.08% with a bearish technical signal despite oscillators showing some bullish momentum. The company shows declining revenue from $208M in 2022 to $148M in 2025 with persistent net losses, though Q2 2026 EPS beat expectations. Valuation metrics show low P/S (0.88) and P/B (0.2) ratios, while analyst sentiment is split evenly between Buy and Hold recommendations.
The outlook remains challenging with ongoing revenue declines and negative profitability, though deep valuation discounts and strategic portfolio repositioning offer potential upside. Key risks include high debt levels, office sector headwinds, and execution challenges in turning around financial performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
